Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort

Abstract

Aim: Increased serum alpha-fetoprotein (AFP) levels are associated with specific molecular sub-classes of hepatocellular carcinoma (HCC), supporting AFP as a predictive or therapeutic biomarker for precision treatment of this disease. Considering recent efforts to validate HCC molecular classification systems across different populations, we applied existing signature-based classification templates to Hawaii cohorts and examined whether associations between HCC molecular sub-class, AFP levels, and clinical features found elsewhere can also be found in Hawaii, a region with a unique demographic and risk factor profile for HCC.

Methods: Whole-genome expression profiling was performed on HCC tumors collected from 40 patients following partial hepatectomy. Tumors underwent transcriptome-based categorization into 3 molecular sub-classes (S1, S2, and S3). Patient groups based on molecular sub-class and AFP level were then compared with regards to clinical features and survival. Differences associated with AFP level and other clinical parameters were also examined at the gene signature level by gene set enrichment analysis.

Results: Statistically confident (false discovery rate < 0.05) sub-classifications were made in 98% (39/40) of tumors. Patient sub-groups differed significantly with regards to serum AFP level, with significantly lower levels in the S3 sub-group as compared to S1 (P = 0.048) and S2 (P = 0.010). Serum AFP > 400 ng/mL predicted significant tumor enrichment for genes corresponding to MYC target activation, high cell proliferation, poor clinical prognosis, and the S2 sub-class. AFP > 400 ng/mL and non-S3 tumor classification were found to be significant predictors of overall survival.

Conclusion: Distinct sub-classes of HCC associated with different molecular features and survival outcomes can be detected with statistical confidence in a Pacific Island cohort. Molecular classification signatures and other predictive markers for HCC that are valid for all patient populations are needed to support multi-center efforts to develop targeted therapies for HCC.

Keywords

Hepatocellular carcinoma / alpha-fetoprotein / survival / gene expression / enrichment analysis / molecular signature / Asia-Pacific / Hawaii

References

[1] Ferlay J,Dikshit R,Mathers C,Parkin DM,Bray F.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[2] Torre LA,Ward EM.Global cancer incidence and mortality rates and trends--an update..Cancer Epidemiol Biomarkers Prev2016;25:16-27

[3] Mittal S.Epidemiology of hepatocellular carcinoma: consider the population..J Clin Gastroenterol2013;S2-6 PMCID:PMC3683119

[4] Registry HT.Hawaii Cancer at a Glance: 2009-2013.Honolulu, Hawaii: University of Hawaii Cancer Center;2013; PMCID:PMC3918938

[5] Wong LL,Shvetsov YB,Tang ZY.Liver resection for early hepatocellular cancer: comparison of centers in 3 different countries..World J Hepatol2016;8:1327-35 PMCID:PMC5099585

[6] Ochner M,Wimmer-Kunitomo K.Hepatocellular cancer: risk factors and survival in Pacific Islanders compared to Caucasians in Hawaii..Ethn Dis2010;20:169-73

[7] Wong LL,Ji J.The changing characteristics of hepatocellular cancer in Hawaii over time..Am J Surg2015;210:146-52

[8] Chiang DY,Hoshida Y,Newell P,LeBlanc AC,Thung SN,Tovar V,Ramos AH,Roayaie S,Waxman S,Mazzaferro V,Najfeld V,Sellers WR,Llovet JM.Focal gains of VEGFA and molecular classification of hepatocellular carcinoma..Cancer Res2008;68:6779-88 PMCID:PMC2587454

[9] Goossens N,Hoshida Y.Molecular classification of hepatocellular carcinoma: potential therapeutic implications..Hepat Oncol2015;2:371-9 PMCID:PMC4662420

[10] Hoshida Y,Kobayashi M,Brunet JP,Villanueva A,Ikeda K,Watanabe G,Friedman SL,Llovet JM.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma..Cancer Res2009;69:7385-92 PMCID:PMC3549578

[11] Tan PS,Goossens N,Huang T,Sun X,Koh A,Deshmukh M,Mahajan M,Fiel MI,Kumada H.Clinicopathological indices to predict hepatocellular carcinoma molecular classification..Liver Int2016;36:108-18 PMCID:PMC4674393

[12] Yamashita T,Wang W,Ye Q,Budhu A,Chen Y,Tang ZY.EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma..Cancer Res2008;68:1451-61

[13] Ghouri YA,Rowe JH.Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis..J Carcinog2017;16:1 PMCID:PMC5490340

[14] Li L.Heterogeneity of liver cancer and personalized therapy..Cancer Lett2016;379:191-7

[15] Goossens N,Hoshida Y.Tailored algorithms for hepatocellular carcinoma surveillance: is one-size-fits-all strategy outdated?.Curr Hepatol Rep2017;16:64-71

[16] Chan SL,Lee K,Chan AK.Personalized therapy for hepatocellular carcinoma: where are we now?.Cancer Treat Rev2016;45:77-86

[17] Schulze K.Translating the molecular diversity of hepatocellular carcinoma into clinical practice..Mol Cell Oncol2016;3:e1057316 PMCID:PMC4972123

[18] Marrero JA,Wang Y,Befeler AS,Reddy KR,Llovet JM,Dalhgren J,Lok AS,Srivastava S.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma..Gastroenterology2009;137:110-8 PMCID:PMC2704256

[19] Singal AG,Volk ML,Fontana RJ,Su GL,Marrero JA.Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis..Cancer Epidemiol Biomarkers Prev2012;21:793-9 PMCID:PMC5640437

[20] Giannini EG,Farinati F,Pecorelli A,Di Marco M,Zoli M,Cabibbo G,Gasbarrini A,Foschi FG,Morisco F,Virdone R.Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use..Cancer2014;120:2150-7

[21] Pardee AD,Butterfield LH.Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells..J Immunol2014;193:5723-32 PMCID:PMC4239186

[22] Sauzay C,Bourgeois AM,Chauffert B,Houessinon A.Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma..Clin Chim Acta2016;463:39-44

[23] Xu L,Hoshida Y,Ross K,Wagner SN,Mesirov JP.Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases..Mol Cancer Res2008;6:760-9 PMCID:PMC2756991

[24] Wong LL,Schwartz J,Bhattacharya R,Orloff SL.Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis..Clin Transplant2013;27:E72-9

[25] Subramanian A,Mootha VK,Ebert BL,Paulovich A,Golub TR,Mesirov JP.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles..Proc Natl Acad Sci U S A2005;102:15545-50 PMCID:PMC1239896

[26] Boyault S,de Reynies A,Rebouissou S,Herault A,Belghiti J,Bioulac-Sage P,Zucman-Rossi J.Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets..Hepatology2007;45:42-52

[27] Lee JS,Heo J,Sun Z,Durnez A,Thorgeirsson SS.Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling..Hepatology2004;40:667-76

[28] Galmiche A,Chevet E.Role of the unfolded protein response in tumor cell characteristics and cancer outcome..Curr Opin Oncol2017;29:41-7

[29] Houessinon A,Bochereau F,Nyga R,Degonville J,Saidak Z,Barbare JC,Francois C,Galmiche A.Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib..Cancer Lett2016;370:242-9

[30] Ren B,Takahashi Y,Terragni J,Dynlacht BD.E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints..Genes Dev2002;16:245-56 PMCID:PMC155321

[31] Carr BI,Giannini EG,Ciccarese F,Di Marco M,Zoli M,Caturelli E,Trevisani F.Low alpha-fetoprotein HCC and the role of GGTP..Int J Biol Markers2014;29:e395-402

[32] Goossens N.Personalized management of hepatocellular carcinoma based on molecular information: future prospects..Clin Liver Dis (Hoboken)2015;5:132-5 PMCID:PMC4512174

[33] Finn RS,Dering J,Ginther C,Zhao D,Busuttil RW.Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro..Hepatology2013;57:1838-46

[34] Lee JS.Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer..Hepatology2002;35:1134-43

[35] Zyla J,Weiner J.Ranking metrics in gene set enrichment analysis: do they matter?.BMC Bioinformatics2017;18:256 PMCID:PMC5427619

[36] Totoki Y,Covington KR,Creighton CJ,Tsuji S,Slagle BL,Yamamoto S,Hama N,Hosoda F,Walker K,Gotoh K,Gingras MC,Ojima H,Midorikawa Y,Cotton R,Shibahara J,Guiteau J,Urushidate T,Okada N,Wang M,Dinh H,Kokudo N,Takayama T,Gibbs RA,Aburatani H.Trans-ancestry mutational landscape of hepatocellular carcinoma genomes..Nat Genet2014;46:1267-73